BioWorld

Nov. 1, 2002

Zonagen's Search For Merger Partner Ends With Lavipharm

Zonagen Inc., searching for ways to benefit shareholders for some time, said it is merging with Lavipharm Corp. in a move that should please Zonagen stockholders and fulfill Lavipharm's desire to become a public company. (BioWorld Today) Read More

Embryo Joins Ranks Of Human Subjects Requiring Protection

A Newly Discovered Bacterium Lays Low Trichloroethane, A Worldwide Industrial Pollutant

SuperGen Plans Orathecin NDA Following Consultation With FDA

Cerus Gets $50M Loan Pledge From Intercept Partner Baxter

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...